{"product_id":"targeted-radiation-therapy-prrt-for-advanced-medullary-thyroid-cancer-what-patients-should-know","title":"Targeted Radiation Therapy (PRRT) for Advanced Medullary Thyroid Cancer: What Patients Should Know","description":"\u003cbody\u003e\n\n\n\u003cp\u003eThis systematic review and meta-analysis evaluated whether a targeted form of radiation therapy called peptide receptor radionuclide therapy (PRRT) is safe and effective for patients with advanced medullary thyroid cancer (MTC) that has spread or progressed despite treatment. Researchers combined data from 11 studies covering 177 patients who received 498 treatment cycles, and found that disease was controlled in more than half of patients by both imaging and blood-based measures, with a generally favorable safety profile. Of the two most commonly used PRRT agents, [177Lu]Lu-DOTATATE showed slightly better tumor control on imaging (64% versus 50%) and substantially fewer side effects (7% versus 24%) compared with [90Y]Y-DOTATOC.\u003c\/p\u003e\n\n\u003ch1\u003eTargeted Radiation Therapy (PRRT) for Advanced Medullary Thyroid Cancer: What Patients Should Know\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eUnderstanding Medullary Thyroid Cancer and the Treatment Gap\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#why-study\"\u003eWhy Researchers Conducted This Study\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#included-studies\"\u003eThe 11 Studies: Patients, Treatments, and Study Designs\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#overall-results\"\u003eKey Findings: Overall Results Across All Treatments\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#agent-comparison\"\u003eKey Findings: Comparing [177Lu]Lu-DOTATATE and [90Y]Y-DOTATOC\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#safety\"\u003eSide Effects: What the Safety Analysis Found\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What This Study Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations and Future Directions\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003ePRRT controlled disease by imaging in 58% of 177 advanced medullary thyroid cancer patients.\u003c\/li\u003e\n\u003cli\u003eStable disease was the most common imaging benefit, seen in 53% of patients.\u003c\/li\u003e\n\u003cli\u003eBlood marker disease control occurred in 52% of patients; overall biomarker response was 32%.\u003c\/li\u003e\n\u003cli\u003e[177Lu]Lu-DOTATATE had 64% imaging disease control and 7% side effects, versus 50% and 24% for [90Y]Y-DOTATOC.\u003c\/li\u003e\n\u003cli\u003eSevere side effects occurred in only about 3% of patients, but evidence came mostly from retrospective studies without randomized trials.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eUnderstanding Medullary Thyroid Cancer and the Treatment Gap\u003c\/h2\u003e\n\n\u003cp\u003eMedullary thyroid cancer (MTC) is a rare type of neuroendocrine tumor (a cancer that arises from hormone-producing cells) that develops in the parafollicular C cells of the thyroid gland. These are the cells responsible for producing calcitonin, a hormone that helps regulate calcium levels in the body.\u003c\/p\u003e\n\n\u003cp\u003eMTC represents only 1–2% of all thyroid cancers. It is much less common than the differentiated thyroid cancers (papillary and follicular), which most people associate with thyroid disease.\u003c\/p\u003e\n\n\u003cp\u003eThe disease occurs in two main forms:\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSporadic MTC\u003c\/strong\u003e (75–80% of cases): occurs in older adults without a family history of the disease\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFamilial MTC\u003c\/strong\u003e (20–25% of cases): inherited and often linked to a genetic condition called multiple endocrine neoplasia type 2 (MEN2), which predisposes people to tumors in multiple hormone-producing glands\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cp\u003eSurgery to remove the tumor is generally curative when the cancer is confined to the thyroid. However, a subset of MTC tumors behaves aggressively and spreads (metastasizes) to other parts of the body. For these patients with progressive or metastatic disease, treatment has historically been challenging.\u003c\/p\u003e\n\n\u003cp\u003eTraditional chemotherapy has shown only limited benefit. Objective response rates (ORR, meaning the percentage of patients whose tumors measurably shrink) are typically below 20%. In recent years, two targeted oral medications called tyrosine kinase inhibitors (TKIs) — \u003cstrong\u003evandetanib\u003c\/strong\u003e and \u003cstrong\u003ecabozantinib\u003c\/strong\u003e — have been approved by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for progressive or metastatic MTC.\u003c\/p\u003e\n\n\u003cp\u003eHowever, these drugs come with a significant burden. High-grade adverse events (severe side effects) occur in more than 36% of patients treated with TKIs. This substantial toxicity profile has created a clear need for alternative systemic treatment options that can control the disease without such a heavy side-effect toll.\u003c\/p\u003e\n\n\u003ch2 id=\"why-study\"\u003eWhy Researchers Conducted This Study\u003c\/h2\u003e\n\n\u003cp\u003eRecent advances in the field of radiotheranostics — a term combining \"therapy\" and \"diagnostics\" — have led to the development of drugs that deliver targeted radiation directly to cancer cells. These agents work by attaching to somatostatin receptors (SSTRs), which are proteins found in high numbers on the surface of many neuroendocrine tumor cells.\u003c\/p\u003e\n\n\u003cp\u003eOne such agent, called [177Lu]Lu-DOTATATE, received FDA and EMA approval for gastroenteropancreatic neuroendocrine tumors (GEP-NENs, a type of neuroendocrine tumor arising in the digestive system) after the landmark NETTER-1 trial demonstrated its effectiveness. This approval raised the question: could the same strategy work for medullary thyroid cancer, which is also a neuroendocrine tumor that often expresses somatostatin receptors?\u003c\/p\u003e\n\n\u003cp\u003eWhile several narrative reviews (expert summaries without systematic methodology) suggested that SSTR-based peptide receptor radionuclide therapy (PRRT) might benefit MTC patients, no systematic review or meta-analysis had yet pooled the available evidence specifically for progressive or metastatic MTC. This study aimed to fill that gap by systematically collecting, evaluating, and statistically combining all published clinical data on the safety and efficacy of SSTR PRRT in this patient population.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThis meta-analysis was carefully planned and registered in advance in an international database of systematic reviews. The registration number is PROSPERO ID: CRD42022350984. The researchers followed the PRISMA 2020 guidelines, which are internationally recognized standards for reporting systematic reviews and meta-analyses.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSearch strategy.\u003c\/strong\u003e Three major medical databases — PubMed, Scopus, and Web of Science — were systematically searched from their inception dates through April 22, 2025. Three authors independently conducted the searches using MeSH- and Emtree-based keywords to ensure comprehensive coverage.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eEligibility criteria.\u003c\/strong\u003e To be included, studies had to be original research articles that specifically assessed the safety and efficacy of SSTR PRRT in patients with MTC in clinical (human) settings. The researchers excluded duplicate publications, book chapters, case reports, case series, review articles, conference proceedings, meeting abstracts, preclinical studies, and articles unrelated to the research question.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eData extraction.\u003c\/strong\u003e From each study that met the inclusion criteria, the researchers extracted detailed information including the primary author's name, year of publication, country, research design, patient cohort size, imaging modality used, median patient age, prior lines of therapy, the specific PRRT agent used, number of treatment cycles, dosing strategy, biochemical markers, imaging evaluation results, and the response criteria applied for both biochemical and imaging endpoints.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eQuality assessment.\u003c\/strong\u003e The methodological quality of each included study was assessed using the National Institutes of Health (NIH) Quality Assessment Tool for Observational Cohorts and Cross-Sectional Studies. This tool evaluates 14 criteria and assigns studies to one of three quality levels:\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\"Good\"\u003c\/strong\u003e: scores of 9–14 points\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\"Fair\"\u003c\/strong\u003e: scores of 5–8 points\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\"Poor\"\u003c\/strong\u003e: scores of 0–4 points\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cp\u003e\u003cstrong\u003eStatistical analysis.\u003c\/strong\u003e Pooled estimates of key outcomes — including the disease control rate (DCR, the percentage of patients whose disease either stabilizes or shrinks), overall response rate (ORR), partial response (PR) rate, stable disease (SD) rate, complete response (CR) rate, and adverse event rate — were calculated with corresponding 95% confidence intervals (CIs, a range that indicates the statistical certainty of the estimate).\u003c\/p\u003e\n\n\u003cp\u003eThe researchers applied a fixed-effects model when fewer than five studies were available for a given analysis, and a random-effects model when five or more studies were available. Publication bias (the tendency for positive results to be published more often than negative ones) was assessed using Egger's test when at least three studies were available. For analyses with ten or more studies, additional visual tools (Doi plots and the Luis Furuya–Kanamori index) were used.\u003c\/p\u003e\n\n\u003cp\u003eBetween-study heterogeneity (the degree to which study results differ from each other) was quantified using the inconsistency index (I²). Values below 50% were considered low to moderate heterogeneity; values above 50% indicated substantial to considerable heterogeneity. A p-value below 0.05 was considered statistically significant. All analysis was performed using Stata software, version 17.0.\u003c\/p\u003e\n\n\u003ch2 id=\"included-studies\"\u003eThe 11 Studies: Patients, Treatments, and Study Designs\u003c\/h2\u003e\n\n\u003cp\u003eThe initial literature search retrieved 626 articles from the three databases: 217 from PubMed, 209 from Scopus, and 200 from Web of Science. After removing 357 duplicates, 269 titles and abstracts were screened. Most records were excluded because they did not meet the study objectives. Ultimately, 11 articles fulfilled all eligibility criteria and were included in the final analysis.\u003c\/p\u003e\n\n\u003cp\u003eThese 11 studies, published between 2003 and 2023, included a total of 177 MTC patients who received 498 SSTR PRRT treatment cycles. The median age of patients ranged from 35 to 62 years across the studies, with a slight male predominance (57% male).\u003c\/p\u003e\n\n\u003cp\u003eStudy designs varied:\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e9 studies\u003c\/strong\u003e were retrospective (looking back at medical records)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2 studies\u003c\/strong\u003e were prospective (following patients forward in time)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cp\u003eIn terms of disease type, familial MTC was reported in only 15 patients across four studies, while the vast majority of patients (\u0026gt;91%) had the sporadic form of the disease.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBaseline imaging approaches.\u003c\/strong\u003e Before treatment, doctors used imaging scans to assess the extent of disease:\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e7 studies\u003c\/strong\u003e used [111In]In-octreotide scanning (SPECT, single photon emission computed tomography)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e4 studies\u003c\/strong\u003e used [68Ga]Ga-DOTA-peptide scanning (PET, positron emission tomography)\u003c\/li\u003e\n\u003c\/ul\u003e\nThe Krenning score, a visual grading system that measures how strongly tumors take up the radioactive tracer, was used to assess baseline molecular uptake in 9 studies.\n\n\u003cp\u003e\u003cstrong\u003eDosing schedules.\u003c\/strong\u003e Most studies (8 of 11, or 73%) administered PRRT in a cyclic dosage format (discrete treatment cycles). A smaller proportion (3 studies, 27%) used a fractionated dosing regimen, in which the total dose is divided into smaller fractions given more frequently.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eResponse evaluation.\u003c\/strong\u003e Imaging responses were evaluated using conventional imaging (CT or MRI) in 6 studies and molecular imaging (PET or SPECT) in 5 studies. Biochemical response was assessed by measuring changes in blood levels of two tumor markers: serum thyrocalcitonin (TC, also called calcitonin — the hormone produced by the C cells) and carcinoembryonic antigen (CEA, a general tumor marker).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSafety reporting.\u003c\/strong\u003e Nine studies reported side effects using the Common Terminology Criteria for Adverse Events (CTCAE, a standardized grading system where grade 1 is mild and grade 4–5 is severe or fatal). The remaining two studies used the World Health Organization (WHO) toxicity criteria.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGeographic distribution.\u003c\/strong\u003e Seven studies were conducted in Europe (Netherlands, Italy, Switzerland, Germany), two in India, one in Iran, and one in Brazil. The specific countries were: Netherlands (2 studies), Italy (2 studies), Switzerland (2 studies), Germany (1 study), India (2 studies), Iran (1 study), and Brazil (1 study).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eQuality ratings.\u003c\/strong\u003e Seven studies were rated as \"good\" quality and four as \"fair\" quality. No studies were rated as \"poor.\"\u003c\/p\u003e\n\n\u003ch2 id=\"overall-results\"\u003eKey Findings: Overall Results Across All Treatments\u003c\/h2\u003e\n\n\u003cp\u003eWhen the data from all eligible studies were pooled together, the results showed that SSTR PRRT meaningfully controls disease in a substantial proportion of patients with advanced MTC.\u003c\/p\u003e\n\n\u003ch3\u003eBiochemical (Blood Marker) Response\u003c\/h3\u003e\n\n\u003cp\u003eBiochemical response refers to whether blood levels of calcitonin and CEA decreased after treatment. These markers are important because they reflect the overall tumor burden in the body.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDisease control rate (DCR):\u003c\/strong\u003e Six studies, covering 362 PRRT cycles given to 118 patients, reported biochemical disease control data. The pooled disease control rate was \u003cstrong\u003e52%\u003c\/strong\u003e (95% CI: 43–61%). This means that slightly more than half of patients (about 1 in 2) achieved either stable or reduced tumor marker levels. There was no significant heterogeneity between studies or evidence of publication bias (p \u0026gt; 0.76 for both), meaning the results were consistent across studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOverall response rate (ORR):\u003c\/strong\u003e Four studies, covering 302 cycles given to 103 patients, reported biochemical response data. The pooled overall response rate was \u003cstrong\u003e32%\u003c\/strong\u003e (95% CI: 23–42%), meaning about 1 in 3 patients had a meaningful reduction in tumor markers. No significant publication bias was detected (p = 0.81).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eType of response:\u003c\/strong\u003e Partial response (PR, meaning a significant but incomplete reduction in tumor markers) was the most common favorable biochemical outcome, achieved in \u003cstrong\u003e27%\u003c\/strong\u003e of patients (95% CI: 18–36%), followed by stable disease (SD) and complete response (CR).\u003c\/p\u003e\n\n\u003ch3\u003eImaging (Radiological) Response\u003c\/h3\u003e\n\n\u003cp\u003eImaging response refers to whether tumors visibly shrink or stabilize on CT, MRI, or molecular imaging scans.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDisease control rate:\u003c\/strong\u003e All 11 studies, covering 498 cycles given to 177 patients, reported imaging-based disease control. The pooled DCR was \u003cstrong\u003e58%\u003c\/strong\u003e (95% CI: 46–70%), with no significant heterogeneity (I² = 48.4%) or publication bias (p \u0026gt; 0.07 for both). This means that more than half of patients (roughly 6 in 10) achieved tumor stabilization or shrinkage visible on scans.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOverall response rate:\u003c\/strong\u003e Seven studies, covering 392 cycles given to 142 patients, reported imaging response data. The pooled ORR was \u003cstrong\u003e17%\u003c\/strong\u003e (95% CI: 7–26%). No significant publication bias was detected (I² = 43.6%, p = 0.09).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eType of response:\u003c\/strong\u003e Stable disease (SD) was the most frequent imaging outcome, observed in a cumulative \u003cstrong\u003e53%\u003c\/strong\u003e of patients (95% CI: 44–62%). This means that for many patients, the main benefit of PRRT was keeping the cancer from growing rather than shrinking it. Partial responses were observed in a smaller proportion, followed by complete responses (CR), which were rare.\u003c\/p\u003e\n\n\u003ch2 id=\"agent-comparison\"\u003eKey Findings: Comparing [177Lu]Lu-DOTATATE and [90Y]Y-DOTATOC\u003c\/h2\u003e\n\n\u003cp\u003eThe two most commonly used PRRT agents in the included studies were [177Lu]Lu-DOTATATE and [90Y]Y-DOTATOC. These differ in the radioactive isotope attached to the somatostatin-targeting molecule, which affects the type and depth of radiation delivered to tumors. The researchers performed subgroup analyses to compare them directly.\u003c\/p\u003e\n\n\u003ch3\u003e[177Lu]Lu-DOTATATE: Results from 5 Studies\u003c\/h3\u003e\n\n\u003cp\u003e[177Lu]Lu-DOTATATE is the agent that received FDA and EMA approval for gastroenteropancreatic neuroendocrine tumors. In this analysis of MTC patients, it showed the following results:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBiochemical (blood marker) responses:\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eDisease control rate: \u003cstrong\u003e51%\u003c\/strong\u003e (95% CI: 38–64%) based on 3 studies\u003c\/li\u003e\n  \u003cli\u003eOverall response rate: \u003cstrong\u003e37%\u003c\/strong\u003e (95% CI: 23–58%) based on 2 studies\u003c\/li\u003e\n  \u003cli\u003ePartial response: 27% of patients\u003c\/li\u003e\n  \u003cli\u003eStable disease: 26% of patients\u003c\/li\u003e\n  \u003cli\u003eComplete response: 12% of patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cp\u003e\u003cstrong\u003eImaging responses:\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eDisease control rate: \u003cstrong\u003e64%\u003c\/strong\u003e (95% CI: 52–75%) based on 5 studies, with no significant heterogeneity or publication bias (p \u0026gt; 0.4 for both)\u003c\/li\u003e\n  \u003cli\u003eOverall response rate: \u003cstrong\u003e18%\u003c\/strong\u003e (95% CI: 10–49%) based on 3 studies\u003c\/li\u003e\n  \u003cli\u003eStable disease was the most common outcome: 53% (95% CI: 35–70%)\u003c\/li\u003e\n  \u003cli\u003ePartial response: 18% of cases\u003c\/li\u003e\n  \u003cli\u003eComplete responses: none recorded on imaging assessments\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003ch3\u003e[90Y]Y-DOTATOC: Results from Up to 4 Studies\u003c\/h3\u003e\n\n\u003cp\u003e[90Y]Y-DOTATOC uses a different radioactive isotope (yttrium-90) that delivers radiation with higher energy and deeper tissue penetration. Its results in MTC patients were as follows:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBiochemical responses:\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eDisease control rate: \u003cstrong\u003e52%\u003c\/strong\u003e (95% CI: 43–58%) based on 2 studies\u003c\/li\u003e\n  \u003cli\u003eOverall response rate: \u003cstrong\u003e29%\u003c\/strong\u003e (95% CI: 17–42%) based on 2 studies\u003c\/li\u003e\n  \u003cli\u003ePartial response: 27% of patients\u003c\/li\u003e\n  \u003cli\u003eStable disease: 23% of patients\u003c\/li\u003e\n  \u003cli\u003eComplete response: 5% of patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cp\u003e\u003cstrong\u003eImaging responses:\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eDisease control rate: \u003cstrong\u003e50%\u003c\/strong\u003e (95% CI: 28–72%) based on 4 studies\u003c\/li\u003e\n  \u003cli\u003eOverall response rate: \u003cstrong\u003e20%\u003c\/strong\u003e (95% CI: 8–37%) based on 3 studies\u003c\/li\u003e\n  \u003cli\u003eStable disease: 50% of patients\u003c\/li\u003e\n  \u003cli\u003ePartial response: 25% of patients\u003c\/li\u003e\n  \u003cli\u003eComplete response: 10% of patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003ch3\u003eDirect Comparison: Which Agent Performed Better?\u003c\/h3\u003e\n\n\u003cp\u003eWhen the researchers directly compared the two agents, several differences emerged:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eImaging disease control:\u003c\/strong\u003e [177Lu]Lu-DOTATATE achieved a slightly higher imaging DCR (64% versus 50%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBiochemical disease control:\u003c\/strong\u003e The two agents were comparable (51% for [177Lu]Lu-DOTATATE versus 52% for [90Y]Y-DOTATOC)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBiochemical overall response:\u003c\/strong\u003e [177Lu]Lu-DOTATATE achieved a higher biochemical ORR (37% versus 29%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOverall toxicity:\u003c\/strong\u003e [177Lu]Lu-DOTATATE had a substantially lower overall toxicity rate (7% versus 24%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKidney (renal) toxicity:\u003c\/strong\u003e No renal toxicity was observed with [177Lu]Lu-DOTATATE, whereas [90Y]Y-DOTATOC caused kidney toxicity at a pooled rate of 6%, mostly low-grade\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eWhy might [90Y]Y-DOTATOC cause more side effects? The researchers explain that this is likely due to its higher β-emission energy, greater tissue penetration depth, and increased off-target radiation exposure to healthy tissues. However, they also note that differences in dosing regimens across studies — such as single versus multiple cycles, total cumulative activity, and the use of kidney-protective agents — may have influenced the observed toxicity patterns.\u003c\/p\u003e\n\n\u003ch2 id=\"safety\"\u003eSide Effects: What the Safety Analysis Found\u003c\/h2\u003e\n\n\u003cp\u003eUnderstanding the side-effect profile of any cancer treatment is essential for patients weighing their options. The safety analysis pooled data from the studies that documented treatment-related toxicities.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOverall toxicity rate.\u003c\/strong\u003e Seven of the 11 studies documented PRRT-associated toxicities. The pooled incidence rate of any side effect was \u003cstrong\u003e15%\u003c\/strong\u003e (95% CI: 5–29%). This means that about 1 in 7 patients experienced some form of treatment-related side effect.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eTypes of side effects.\u003c\/strong\u003e The majority of adverse effects affected two body systems:\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGastrointestinal system\u003c\/strong\u003e (digestive tract): including nausea, vomiting, or abdominal discomfort\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHematopoietic system\u003c\/strong\u003e (blood and bone marrow): including lowered blood cell counts\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cp\u003e\u003cstrong\u003eSeverity of side effects.\u003c\/strong\u003e An important finding was that low-grade toxicities (grade 1–2, meaning mild to moderate) predominated over high-grade events (grade 3–4, meaning severe or potentially life-threatening). The pooled rate was \u003cstrong\u003e13% for low-grade versus 3% for high-grade events\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eHigh-grade events were rare overall. Across all studies, only \u003cstrong\u003efour instances of grade 3 hematotoxicity\u003c\/strong\u003e (severe blood-related toxicity) and \u003cstrong\u003eone instance of grade 4 nephrotoxicity\u003c\/strong\u003e (severe kidney toxicity) were reported.\u003c\/p\u003e\n\n\u003ch3\u003eSide Effects by Treatment Agent\u003c\/h3\u003e\n\n\u003cp\u003e\u003cstrong\u003e[177Lu]Lu-DOTATATE safety profile.\u003c\/strong\u003e The pooled incidence of any-grade toxicity was just \u003cstrong\u003e7%\u003c\/strong\u003e (95% CI: 0–22%) across the three studies that reported safety data. The breakdown was:\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eGrade 1–2 gastrointestinal effects: 3% (95% CI: 1–7%)\u003c\/li\u003e\n  \u003cli\u003eGrade 1–2 hematologic (blood) toxicity: 1% (95% CI: 0–3%)\u003c\/li\u003e\n  \u003cli\u003eNotably, \u003cstrong\u003eno high-grade hematologic or gastrointestinal adverse events were reported\u003c\/strong\u003e at all\u003c\/li\u003e\n  \u003cli\u003eNo kidney toxicity was observed\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cp\u003e\u003cstrong\u003e[90Y]Y-DOTATOC safety profile.\u003c\/strong\u003e Any-grade adverse events occurred in \u003cstrong\u003e24%\u003c\/strong\u003e (95% CI: 7–45%) of patients across four studies. The breakdown was:\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eLow-grade (grade 1–2) toxicity: 18% (95% CI: 6–33%)\u003c\/li\u003e\n  \u003cli\u003eHigh-grade (grade 3–4) adverse events: 3% (95% CI: 0–12%)\u003c\/li\u003e\n  \u003cli\u003eGrade 1–2 gastrointestinal effects: 29% (95% CI: 12–55%) — notably higher than with [177Lu]Lu-DOTATATE\u003c\/li\u003e\n  \u003cli\u003eGrade 1–2 hematologic toxicity: 17% of patients\u003c\/li\u003e\n  \u003cli\u003eGrade 1 kidney toxicity: 6% of patients\u003c\/li\u003e\n  \u003cli\u003eGrade 3 hematologic toxicity: 2% of patients\u003c\/li\u003e\n  \u003cli\u003eGrade 4 kidney toxicity: 1% of patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cp\u003eIn plain terms, [90Y]Y-DOTATOC was associated with roughly three times more side effects overall than [177Lu]Lu-DOTATATE, and unlike [177Lu]Lu-DOTATATE, it carried a small but real risk of kidney damage.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThese findings have several important implications for patients living with advanced medullary thyroid cancer:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e1. A new treatment option is emerging.\u003c\/strong\u003e For patients whose MTC has progressed despite surgery, chemotherapy, or TKI therapy, SSTR PRRT offers a promising alternative. This meta-analysis shows that disease can be controlled in more than half of patients — about 52% by blood marker criteria and 58% by imaging criteria.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e2. Disease stabilization is a realistic goal.\u003c\/strong\u003e Patients should understand that the most common benefit of PRRT is keeping the cancer from growing (stable disease) rather than shrinking it. On imaging, stable disease was seen in 53% of patients overall. In cancer care, stopping tumor growth is a meaningful and valuable outcome that can translate into more stable health and quality of life.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e3. Blood markers matter.\u003c\/strong\u003e The biochemical response rates are particularly notable: about one-third of patients (32%) achieved a meaningful reduction in calcitonin or CEA levels. For patients who can see their tumor markers dropping on blood tests, this provides tangible evidence that the treatment is working.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e4. The side-effect profile compares favorably to alternatives.\u003c\/strong\u003e With the currently approved TKI drugs (vandetanib and cabozantinib), more than 36% of patients experience severe (high-grade) side effects. By contrast, this analysis of PRRT found that severe side effects occurred in only about 3% of patients overall. For [177Lu]Lu-DOTATATE specifically, severe side effects were essentially absent in the pooled data.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e5. The choice of agent matters.\u003c\/strong\u003e If both agents are available, the data suggest that [177Lu]Lu-DOTATATE may offer a better balance of effectiveness and safety. It achieved slightly better imaging disease control (64% versus 50%), comparable blood-marker disease control (51% versus 52%), a higher blood-marker response rate (37% versus 29%), and a substantially better safety profile — especially regarding the kidneys.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e6. PRRT requires SSTR expression.\u003c\/strong\u003e For PRRT to work, tumors must express somatostatin receptors, which is confirmed before treatment through imaging scans (as done in the included studies, using either [111In]In-octreotide SPECT or [68Ga]Ga-DOTA-peptide PET scans). Patients who are considering PRRT should discuss with their care team whether their tumors demonstrate sufficient receptor expression on these scans.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What This Study Could Not Prove\u003c\/h2\u003e\n\n\u003cp\u003eWhile this meta-analysis provides the most comprehensive evidence to date on PRRT for MTC, the researchers acknowledge several important limitations that patients and clinicians should keep in mind:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePredominance of retrospective, single-center studies.\u003c\/strong\u003e Nine of the 11 included studies were retrospective (looking back at medical records) and were conducted at single institutions. This study design carries inherent risks of bias. Only two studies were prospective (following patients forward in time).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGeographic concentration.\u003c\/strong\u003e Seven of the 11 studies came from Europe, with the remainder from India (2), Iran (1), and Brazil (1). It is unclear whether results would be similar in other patient populations or health care settings.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHeterogeneity of treatments and patients.\u003c\/strong\u003e The studies varied in the PRRT agents used, dosing regimens (cyclic versus fractionated), number of cycles, total radiation activity administered, and use of kidney-protective medications. Some studies included heavily pre-treated patients who had received four or more prior lines of therapy. This variability in patient history could affect tumor biology, treatment resistance patterns, and toxicity risk in ways that the meta-analysis could not fully account for.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLimited ability to perform deeper statistical analysis.\u003c\/strong\u003e While subgroup analyses addressed some of the variability between studies, meta-regression (a statistical technique that could have examined how specific factors influence outcomes) was not possible due to the limited number of studies. Correlation analyses between how much radiation patients received and how likely they were to experience side effects could not be performed for the [90Y]Y-DOTATOC data.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eInsufficient data on [111In]In-octreotide.\u003c\/strong\u003e The researchers could not evaluate the safety and efficacy of [111In]In-octreotide as a therapeutic agent because only single studies were available — not enough for pooled statistical analysis.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNo randomized controlled trials.\u003c\/strong\u003e None of the included studies were randomized controlled trials (the gold standard for medical evidence). This means the results should be interpreted as promising but not definitive proof of superiority over other treatments.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations and Future Directions\u003c\/h2\u003e\n\n\u003cp\u003eBased on their findings, the researchers make several recommendations for the future of PRRT in medullary thyroid cancer:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFor clinical practice:\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eSSTR PRRT should be considered a viable therapeutic option for patients with metastatic or progressive MTC, particularly for those who have exhausted or cannot tolerate other treatment options\u003c\/li\u003e\n  \u003cli\u003e[177Lu]Lu-DOTATATE appears to offer the most favorable balance of disease control and safety based on currently available data\u003c\/li\u003e\n  \u003cli\u003eKidney function monitoring is advisable, especially for patients receiving [90Y]Y-DOTATOC, given its small but real risk of even high-grade kidney toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cp\u003e\u003cstrong\u003eFor future research:\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eStandardized eligibility criteria should be developed so that future studies enroll similar patient populations, making results more comparable\u003c\/li\u003e\n  \u003cli\u003eHarmonized imaging protocols should be adopted across centers to ensure consistent response assessment\u003c\/li\u003e\n  \u003cli\u003eAdequately powered, multicenter randomized controlled trials are urgently needed to definitively establish the role of PRRT in MTC and to compare it head-to-head with standard treatments like TKIs\u003c\/li\u003e\n  \u003cli\u003eCorrelation analyses between toxicity and cumulative administered activity of [90Y]Y-DOTATOC should be performed to better define dose–toxicity relationships and optimize therapeutic safety\u003c\/li\u003e\n  \u003cli\u003eFuture investigations should explore how prior treatment history affects PRRT outcomes, so that doctors can better select which patients will benefit most\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\n\u003cp\u003eThe researchers conclude that SSTR PRRT is a promising therapeutic option for patients with advanced medullary thyroid cancer, achieving reliable disease control — in more than half of patients by both imaging and biochemical measures — with a favorable safety profile that compares well with currently approved systemic therapies. For patients running out of options, this targeted radiation approach offers genuine hope.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is peptide receptor radionuclide therapy (PRRT) for medullary thyroid cancer?\u003c\/h3\u003e\n\u003cp\u003ePRRT is a targeted radiation treatment that attaches a radioactive substance to a molecule that seeks out somatostatin receptors on tumor cells. In this analysis of 177 patients with advanced medullary thyroid cancer, disease was controlled in more than half of patients by imaging and blood marker tests. It is given in cycles.\u003c\/p\u003e\n\u003ch3\u003eWho might be considered for PRRT for advanced medullary thyroid cancer?\u003c\/h3\u003e\n\u003cp\u003ePRRT may be an option for patients with metastatic or progressive medullary thyroid cancer, especially those who have exhausted or cannot tolerate other treatments like tyrosine kinase inhibitors. Before treatment, imaging scans must show that the tumors have enough somatostatin receptors. In the analyzed studies, most patients had sporadic disease and many had prior treatments.\u003c\/p\u003e\n\u003ch3\u003eHow effective is PRRT at controlling advanced medullary thyroid cancer?\u003c\/h3\u003e\n\u003cp\u003eAcross 11 studies, imaging showed disease control in 58% of patients, meaning tumors stabilized or shrank. Stable disease was the most common imaging outcome, seen in 53%. Blood marker disease control was 52%. Overall response by imaging, meaning tumor shrinkage, was 17%. Stabilization is often the main benefit.\u003c\/p\u003e\n\u003ch3\u003eWhat side effects can PRRT cause for medullary thyroid cancer?\u003c\/h3\u003e\n\u003cp\u003eIn this analysis, about 1 in 7 patients experienced any side effect. Most were mild to moderate, like nausea, vomiting, or low blood counts. Severe side effects occurred in about 3% of patients. The [177Lu]Lu-DOTATATE agent had fewer side effects than [90Y]Y-DOTATOC, and no kidney toxicity was seen with [177Lu]Lu-DOTATATE.\u003c\/p\u003e\n\u003ch3\u003eWhich PRRT agent appears better for medullary thyroid cancer based on this review?\u003c\/h3\u003e\n\u003cp\u003eComparing the two most used agents, [177Lu]Lu-DOTATATE showed slightly higher imaging disease control (64% versus 50%) and fewer overall side effects (7% versus 24%). Blood marker disease control was similar. [177Lu]Lu-DOTATATE had no observed kidney toxicity, while [90Y]Y-DOTATOC had a small kidney toxicity risk. These findings are from pooled observational studies.\u003c\/p\u003e\n\u003ch3\u003eWhat limitations should I know about this PRRT evidence?\u003c\/h3\u003e\n\u003cp\u003eThis was a meta-analysis of 11 studies, mostly retrospective and single-center, with no randomized trials. Seven of 11 studies were from Europe. Treatments varied in dosing and patient history. The results are promising but not definitive proof that PRRT is superior to other treatments. Discuss with your oncology team whether PRRT is appropriate for your situation.\u003c\/p\u003e\n\u003ch3\u003eMy medullary thyroid cancer has spread despite treatment — should I ask for a second opinion before deciding between PRRT and a targeted TKI drug?\u003c\/h3\u003e\n\u003cp\u003eA second opinion is worth seeking if your medullary thyroid cancer has progressed or spread and your doctor has suggested PRRT or a TKI. No randomized controlled trial has compared these approaches directly, so treatment choice can be uncertain. In pooled data, PRRT controlled disease in about 52% of patients by blood markers and 58% by imaging; the [177Lu]Lu-DOTATATE form showed better imaging control (64% vs 50%) and fewer side effects (7% vs 24%) than [90Y]Y-DOTATOC, while TKIs cause severe side effects in over 36% of patients. A second opinion can help clarify which option fits your situation. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Safety and efficacy of peptide receptor radionuclide therapy for advanced medullary thyroid cancer: a systematic review and meta-analysis.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Abdlkadir AS, Al-Adhami D, Shi H, Sathekge MM, Sheikha AA, Mohamad I, Kreissl M, Al-Ibraheem A.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Thyroid Research (2026) 19:7\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e https:\/\/doi.org\/10.1186\/s13044-026-00290-x\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRegistration:\u003c\/strong\u003e PROSPERO ID: CRD42022350984\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication type:\u003c\/strong\u003e Open Access review article\u003c\/p\u003e\n\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research. It was written to help patients and caregivers understand the findings of the original scientific study. Anyone considering PRRT or other treatments for medullary thyroid cancer should discuss the risks and benefits with their oncology care team. The original article is available under a Creative Commons Attribution 4.0 International License.\u003c\/p\u003e\n\n\n\u003c\/body\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47576856690844,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/zh\/products\/targeted-radiation-therapy-prrt-for-advanced-medullary-thyroid-cancer-what-patients-should-know","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}